EHA 2017 | Novel agents for myeloma related bone disease
Evangelos Terpos, MD, PhD from the University of Athens, Athens, Greece discusses the major osteoclast inhibitors used to manage myeloma related bone disease. Zoledronic acid is a bisphosphonate that induces the apoptosis of osteoclasts, whereas denosumab inhibits the mechanism of action of osteoclasts. Zoledronic acid is the current standard treatment and more investigation into denosumab is required to decide which agent produces better patient and survival outcomes. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up